A review of rivastigmine: A reversible cholinesterase inhibitor

Clinical Therapeutics

Volumn 25, Issue 6, 2003, Pages 1634-1653

  Williams, Bradley R ^a   Nazarians, Arlette ^a   Gill, Mark A ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Alzheimer's disease; Dementia; ENA 713; ENA 713; Exelon; Rivastigmine

Indexed keywords

ACETYLCHOLINE; ACETYLCHOLINESTERASE; CHOLINE ACETYLTRANSFERASE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CHOLINERGIC RECEPTOR STIMULATING AGENT; CHOLINESTERASE; CHOLINESTERASE INHIBITOR; CYTOCHROME P450 ISOENZYME; DIURETIC AGENT; RIVASTIGMINE; SALICYLIC ACID; SPASMOLYTIC AGENT;

ABDOMINAL PAIN; AGE; AGITATION; ALZHEIMER DISEASE; ANOREXIA; ASTHENIA; BEHAVIOR; CLINICAL TRIAL; COGNITION; COST CONTROL; COUGHING; CREATININE CLEARANCE; DAILY LIFE ACTIVITY; DIARRHEA; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG COST; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEVER; GASTROINTESTINAL SYMPTOM; GENERAL CONDITION IMPROVEMENT; HEADACHE; HUMAN; KIDNEY DISEASE; LIVER CIRRHOSIS; MALAISE; MYALGIA; NAUSEA; NONHUMAN; PREGNANCY; RACE; REVIEW; RHINITIS; SEX; SIDE EFFECT; SOMNOLENCE; SWEATING; TREATMENT CONTRAINDICATION; TREATMENT INDICATION; TREATMENT OUTCOME; URINE INCONTINENCE; VERTIGO; VOMITING; WEIGHT REDUCTION;

EID: 0038721593     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(03)80160-1     Document Type: Article

References (45)

1. Brookmeyer R, Gray S, Kawas C. Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset. Am J Public Health. 1998;88:1337-1342.
2. Evans DA, Funkenstein HH, Albert MS, et al. Prevalence of Alzheimer's disease in a community population of older persons: Higher than previously reported. JAMA. 1989;262:2551-2556.
3. Wernicke TF, Reischies FM. Prevalence of dementia in old age: Clinical diagnosis in subjects aged 95 years and older. Neurology. 1994;44:250-253.
4. Gao S, Hendrie HC, Hall KS, Hui S. The relationships between age, sex, and the incidence of dementia and Alzheimer disease: A meta-analysis. Arch Gen Psychiatry. 1998;55:809-815.
5. Kukull WA, Higdon R, Bowen JD, et al. Dementia and Alzheimer disease incidence: A prospective cohort study. Arch Neurol. 2002;59:1737-1746.
6. Williams BR. Geriatric dementias. In: Koda-Kimble MA, Young LY, eds. Applied Therapeutics - The Clinical Use of Drugs. 7th ed. Philadelphia, Pa: Lippincott, Williams & Wilkins; 2001:98-1-98-17.
7. Cummings JL, Cole G. Alzheimer disease. JAMA. 2002;287:2335-2338.
8. American Psychiatnc Association. Dementia. In: Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Washington, DC: American Psychiatric Association; 1994:133-155.
9. Costa PT Jr, Williams TF, Somerfield M, et al. Clinical Practice Guideline No. 19: Recognition and Initial Assessment of Atzheimer's Disease and Related Dementias. Rockville, Md: US Dept of Health and Human Services, Agency for Health Care Policy and Research; 1996. AHCP publication 97-0702.
10. Francis PT, Palmer AM, Snape M, Wilcock GK. The cholinergic hypothesis of Alzheimer's disease: A review of progress. J Neurol Neurosurg Psychiatr. 1999;66:137-147.
11. Brookmeyer R, Corrada MM, Curriero FC, Kawas C. Survival following a diagnosis of Alzheimer disease. Arch Neurol. 2002;59:1764-1767.
12. Selkoe DJ. Amyloid protein and Alzheimer's disease. Sci Am. 1991;265:68-78.
13. Cummings JL, Vinters HV, Cole GM, Khachaturian ZS. Alzheimer's disease: Etiologies, pathophysiology, cognitive reserve, and treatment opportunities. Neurology. 1998;51(Suppl 1):S2-S17.
14. Poirier J, Delisle MC, Quirion R, et al. Apolipoprotein E4 allele as a predictor of cholinergic deficits and treatment outcome in Alzheimer disease. Proc Natl Acad Sci U S A. 1995;92:12260-12264.
15. Ladner CJ, Lee JM. Pharmacological treatment of Alzheimer disease: The cholinergic hypothesis revisited. J Neuropathol Exp Neurol. 1998;57:719-731.
16. Gauthier S. Advances in the pharmacotherapy of Alzheimer's disease. CMAJ. 2002;166:616-623.
17. Wang HY, Lee DH, D'Andrea MR, et al. Beta-amyloid (1-42) binds to alpha7 nicotinic acetylcholine receptor with high affinity. Implications for Alzheimer's disease pathology. J Bio Chem. 2000;275:5626-5632.
18. Exelon Prescribing Information [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corp; 2002.
19. Polinsky RJ. Clinical pharmacology of rivastigmine: A new-generation acetylcholinesterase inhibitor for the treatment of Alzheimer's disease. Clin Ther 1998;20:634-647.
20. Krall wJ, Sramek JJ, Cutler NR. Cholinesterase inhibitors: A therapeutic strategy for Alzheimer disease. Ann Pharmacother. 1999;33:441-450.
21. Enz A, Amstutz R, Boddeke H, et al. Brain selective inhibition of acetylcholinesterase: A novel approach to therapy for Alzheimer's disease. Prog Brain Res. 1993;98:431-438.
22. Cutler NR, Polinsky RJ, Sramek JJ, et al. Dose-dependent CSF acetylcholinesterase inhibition by SDZ ENA 713 in Alzheimer's disease. Acta Neurol Scand. 1998;97:244-250.
23. Ballard CG. Advances in the treatment of Alzheimer's disease: Benefits of dual cholinesterase inhibition. Eur Neurol. 2002;47:64-70.
24. Darreh-Shori T, Almkvist O, Guan ZZ, et al. Sustained cholinesterase inhibition in AD patients receiving rivastigmine for 12 months. Neurology. 2002;59:563-572.
25. Schran HF, Habucky K, Mancione LC, et al. The effects of renal and hepatic impairment on the disposition of the acetylcholinesterase (ACHE) inhibitor SDZ ENA 713. Pharm Res. 1996;13(9 Suppl):S428. Abstract.
26. Pugh RNH, Murray-Lyon IM, Dawson JL, et al. Transection of the esophagus for bleeding esophageal varices. Br J Surg. 1973;60:646-649.
27. McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984;34:939-944.
28. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state": A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189-198.
29. Rosen WG, Mobs RC, Davis KL. A new rating scale for Alzheimer's disease. Am J Psychiatry. 1984;141:1356-1364.
30. Knopman D, Knapp MJ, Gracon SI, Davis CS. The Clinician Interview-Based Impression (CIBI): A clinician's global change rating scale in Alzheimer's disease. Neurology. 1994;44:2315-2321.
31. DeJong R, Osterlund OW, Roy GW. Measurement of quality-of-life changes in patients with Alzheimer's disease. Clin Ther. 1989;11:545-554.
32. Sramek JJ, Anand R, Wardle TS, et al. Safety/tolerability trial of SDZ ENA 713 in patients with probable Alzheimer's disease. Life Sci. 1996;58:1201-1207.
33. Corey-Bloom J, Anand R, Veach J, et al. A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer's disease. Int J Geriatr Psychopharmacol. 1998;1:55-65.
34. Rosler M, Anand R, Cicin-Sain A, et al. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: International randomised controlled trial. BMJ. 1999;318:633-638.
35. Farlow M, Anand R, Messina J Jr, et al. A 52-week study of the efficacy of rivastigmine in patients with mild to moderately severe Alzheimer's disease. Eur Neurol. 2000;44:236-241.
36. Farlow MR, Hake A, Messina J, et al. Response of patients with Alzheimer disease to rivastigmine treatment is predicted by the rate of disease progression. Arch Neurol. 2001;58:417-422.
37. Babic T, Banfic L, Papa J, et al. Spontaneous rupture of oesophagus (Boerhaave's syndrome) related to rivastigmine. Age Ageing. 2000;29:370-371.
38. Kumar V. Spontaneous rupture of oesophagus (Boerhaave's syndrome) related to rivastigmine. Age Ageing. 2001;30:177.
39. Grossberg GT, Stahelin HB, Messina JC, et al. Lack of adverse pharmacodynamic drug interactions with rivastigmine and twenty-two classes of medications. Int J Geriatr Psychiatry. 2000;15:242-247.
40. Fenn P, Gray A. Estimating long-term cost savings from treatment of Alzheimer's disease: A modelling approach. PharmacoEconomics. 1999;16:165-174.
41. Hauber AB, Gnanasakthy A, Mauskopf JA. Savings in the cost of caring for patients with Alzheimer's disease in Canada: An analysis of treatment with rivastigmine. Clin Ther. 2000;22:439-451.
42. Hauber AB, Gnanasakthy A, Snyder EH, et al. Potential savings in the cost of caring for Alzheimer's disease: Treatment with rivastigmine. PharmacoEconomics. 2000;17:351-360.
43. Baladi JF, Bailey PA, Black S, et al. Rivastigmine for Alzheimer's disease: Canadian interpretation of intermediate outcome measures and cost implications. Clin Ther. 2000;22:1549-1561.
44. Schneider LS, Anand R, Farlow MR. Systematic review of the efficacy of rivastigmine for patients with Alzheimer's disease. Int J Geriatr Psychopharmacol. 1998;1(Suppl 1):S26-S34.
45. Reisberg B, Ferris SH, de Leon MJ, Crook T. The Global Deterioration Scale for assessment of primary degenerative dementia. Am J Psychiatry. 1982;139:1136-1139.